LNP-NAD⁺ is OctaGenix’s premium Lipid Nanoparticle (LNP) delivery platform for NAD⁺ formulations. It’s engineered to protect the active ingredient, support efficient absorption, and enhance NAD⁺ delivery into cells, where it matters most, through a carefully designed pathway for greater consistency and a more reliable therapeutic benefits.
While the exact route can vary by formulation, the delivery logic remains the same:
Protect the Active → Transport it Efficiently → Support Cellular Uptake → Release it inside the Cell.
NAD⁺ is protected within/with the nanoparticle to help reduce exposure to degradation and maintain integrity.
The nanoparticle structure is designed to support higher exposure and more predictable, consistent performance.
Cells can take up LNPs via endocytosis, bringing the particle into the cell inside an internal “cargo bubble” (an endosome).
A defining advantage is enabling release from the endosome into the cell interior (cytoplasm) known as endosomal escape.
Intracellular delivery describes the core engineering goal: Helping NAD⁺ reach the inside of cells by supporting cellular uptake and controlled release, potentially including mechanisms like endosomal escape in well-designed nanoparticle systems.
LNP architecture is designed to help protect NAD⁺ from degradation pathways and support more consistent performance across real-world storage and use conditions.
LNPs can be optimised to interact with cell membranes and support uptake mechanisms, increasing the intracellular availability.
Well-designed LNPs support release from endosomes into the cytoplasm, a key requirement for true intracellular delivery positioning.
Particle size distribution, loading, stability, and reproducibility are central to consistent delivery performance and to premium retail credibility.
| Format | What it is | Strengths | Typical limitations |
|---|---|---|---|
LNP-NAD⁺ |
Engineered Lipid Nanoparticles are designed for stability, uptake support, and intracellular release potential. |
|
|
Liposomal |
Lipid vesicles often used to improve solubility and tolerability. |
|
|
Standard Oral |
Capsules/tablets/powders using conventional excipients. |
• Simple & scalable |
|
Old technologies currently available (and typical limitations)
LNP-NAD⁺ is OctaGenix’s premium Lipid Nanoparticle delivery system for its NAD⁺ formulations. Technology is designed to protect NAD⁺, support absorption, and enhance the delivery of API into cells through engineered uptake and release mechanisms.
It refers to the delivery engineering goal: Ensuring that NAD⁺ can reach the interior of cells by supporting uptake and release (including endosomal escape) in suitable designs.
A simple term is “endosome breakout.” It means the nanoparticle helps the payload escape from the cell’s internal “cargo bubble” (endosome) so it can be released into the cell interior.
No. Liposomes are typically vesicle structures, while LNPs are engineered nanoparticles often optimised for stability, uptake, and intracellular release behaviour. The difference matters when intracellular availability is the objective.
Yes, Only if you can substantiate the figures with appropriate testing and present them with context and disclaimers. For premium retail, science-led language is often stronger than aggressive numbers.
